Posted in | News | Business | Biomaterials

Biomaterials Company RepRegen Receives Regulatory Approval for StronBone

RepRegen™, the ‘smart biomaterials’ company previously known as BioCeramic Therapeutics, announced today that it has received CE marking approval for StronBone™ bioactive glass with Strontium, the first product that will be commercialized from RepRegen’s repair-and-regeneration platform of ‘smart’ biomaterials for hard tissue, such as bone.

“This European regulatory approval enables us to fast-forward the discussions we are having with several potential strategic partners about our hard tissue platform, in general, and our StronBone product, in particular,” said Ian Brown, RepRegen’s CEO.

“We have previously said that the business opportunities ahead of RepRegen are significant and that some of these opportunities are near-term,” added Chairman Dr. Stephen Rietiker. “The Company’s ‘smart’ biomaterials related to its hard tissue platform represent great new medical device products for the orthopedic biomaterials market sector that will be well-received.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.